Compare Stocks: CAPR, SRPT, and PEPG

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$6.10 +6.3%	$8.11	$2.96 ▼ $40.37	N/A	N/A	N/A	3.47 million shs
PEPG PepGen	$2.60 +4.4%	$2.79	$1.31 ▼ $7.80	N/A	N/A	N/A	1.33 million shs
SRPT Sarepta Therapeutics	$18.89 +5.1%	$19.24	$14.68 ▼ $24.68	N/A	N/A	N/A	2.23 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	+6.27%	-7.72%	-27.03%	-8.55%	-1.29%
PEPG PepGen	+4.42%	-9.41%	+0.39%	+52.05%	-52.12%
SRPT Sarepta Therapeutics	+5.06%	-1.46%	+1.18%	+21.64%	-19.62%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$6.10 +6.3%	$8.11	$2.96 ▼ $40.37	N/A	N/A	N/A	3.47 million shs
PEPG PepGen	$2.60 +4.4%	$2.79	$1.31 ▼ $7.80	N/A	N/A	N/A	1.33 million shs
SRPT Sarepta Therapeutics	$18.89 +5.1%	$19.24	$14.68 ▼ $24.68	N/A	N/A	N/A	2.23 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	+6.27%	-7.72%	-27.03%	-8.55%	-1.29%
PEPG PepGen	+4.42%	-9.41%	+0.39%	+52.05%	-52.12%
SRPT Sarepta Therapeutics	+5.06%	-1.46%	+1.18%	+21.64%	-19.62%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAPR Capricor Therapeutics	2.27	Hold	$30.25	395.90% Upside
PEPG PepGen	2.67	Moderate Buy	$11.40	338.46% Upside
SRPT Sarepta Therapeutics	2.00	Hold	$22.88	21.10% Upside

Current Analyst Ratings Breakdown

Latest CAPR, SRPT, and PEPG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/13/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/8/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
10/8/2026	SRPT Sarepta Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Sector Perform	$19.00 ➝ $17.00
10/5/2026	SRPT Sarepta Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/5/2026	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell	$5.00
9/30/2026	SRPT Sarepta Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$23.00 ➝ $20.00
9/28/2026	SRPT Sarepta Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Underperform
9/24/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/23/2026	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
9/22/2026	PEPG PepGen	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/17/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform

(Data available from 10/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAPR Capricor Therapeutics	N/A	-$2.45	N/A	N/A	N/A	N/A	N/A	N/A	11/9/2026 (Estimated)
PEPG PepGen	N/A	-$1.31	N/A	N/A	N/A	N/A	N/A	N/A	11/11/2026 (Estimated)
SRPT Sarepta Therapeutics	N/A	-$2.90	N/A	14.10	N/A	N/A	N/A	N/A	11/5/2026 (Confirmed)

Latest CAPR, SRPT, and PEPG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	PEPG PepGen	-$0.27	N/A	N/A	N/A	N/A	N/A
11/9/2026	Q3 2026	CAPR Capricor Therapeutics	-$0.1278	N/A	N/A	N/A	$41.71 million	N/A
11/5/2026	Q3 2026	SRPT Sarepta Therapeutics	$0.0740	N/A	N/A	N/A	$352.20 million	N/A
8/13/2026	Q2 2026	CAPR Capricor Therapeutics	-$0.5889	-$0.70	-$0.1111	-$0.70	$2.08 million	N/A
8/6/2026	Q2 2026	PEPG PepGen	-$0.2845	-$0.26	+$0.0245	-$0.26	N/A	N/A
8/5/2026	Q2 2026	SRPT Sarepta Therapeutics	$0.2173	$0.64	+$0.4227	-$0.05	$366.39 million	$401.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CAPR Capricor Therapeutics	21.68%
PEPG PepGen	58.01%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
CAPR Capricor Therapeutics	9.20%
PEPG PepGen	1.30%
SRPT Sarepta Therapeutics	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CAPR Capricor Therapeutics	231	N/A	52.79 million	Optionable
PEPG PepGen	57	N/A	68.36 million	Optionable
SRPT Sarepta Therapeutics	835	N/A	98.34 million	Optionable

CAPR, SRPT, and PEPG Headlines

Recent News About These Companies

Sarepta Therapeutics to Present at Upcoming Investor Conferences - October 26, 2026

October 26 at 11:27 PM | biospace.comB

Sarepta Therapeutics' PD Biomarker Data From FSHD, DM1 Studies Will Be in Focus, Wedbush Says

October 26 at 6:26 PM | finance.yahoo.com

Sarepta Therapeutics to Present at Upcoming Investor Conferences

October 26 at 5:00 PM | businesswire.com

Sarepta Therapeutics (SRPT) Receives a Rating Update from a Top Analyst

October 22, 2026 | theglobeandmail.com

Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results

October 22, 2026 | businesswire.com

Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), Sarepta Therapeutics (SRPT) and BioNTech SE (BNTX)

October 20, 2026 | theglobeandmail.com

Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 8.2% - Time to Buy?

October 20, 2026 | marketbeat.com

H.C. Wainwright keeps USD 5 target for Sarepta Therapeutics stock

October 20, 2026 | ad-hoc-news.deA

Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Navigating a 26.53% Potential Upside Amidst Biotechnology Challenges

October 19, 2026 | directorstalkinterviews.com

Cartesian Therapeutics (NASDAQ:RNAC) and Sarepta Therapeutics (NASDAQ:SRPT) Head to Head Contrast

October 19, 2026 | americanbankingnews.com

Sarepta presents 80 percent DM1 data for Sarepta Therapeutics stock

October 18, 2026 | ad-hoc-news.deA

What Is The Case For Waiting On Moderna Stock?

October 17, 2026 | trefis.comT

Leerink Partners Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)

October 16, 2026 | theglobeandmail.com

Sarepta Therapeutics Faces New Growth Opportunity Emerging From SiRNA Programs, Wedbush Says

October 16, 2026 | finance.yahoo.com

Sarepta Therapeutics: Buy Rating Reiterated on Expanding RNA Pipeline; Price Target Maintained at $35

October 16, 2026 | tipranks.com

Sarepta Therapeutics, Inc. Presents New Preclinical Data Demonstrating Robust Knockdown Of Pathogenic DMPK RNA In The Nucleus With SRP-1003 In DM1 At 2026 Oligonucleotide ...

October 15, 2026 | marketscreener.comM

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide ...

October 15, 2026 | marketscreener.comM

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

October 14, 2026 | finance.yahoo.com

October 14, 2026 | businesswire.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Has Average Target Price of $22.59

October 13, 2026 | marketbeat.com

Global Capsid Tropism Screening Platforms Market Report 2026 | Capitalize on 14.4% CAGR to $1.45B by 2030 as Sarepta, Voyager, REGENXBIO and Dyno Scale AI and NGS Screening

October 12, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR, SRPT, and PEPG Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

$6.10 +0.36 (+6.27%)

Closing price 10/27/2026 04:00 PM Eastern

Extended Trading

$6.08 -0.01 (-0.25%)

As of 10/27/2026 07:58 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

PepGen NASDAQ:PEPG

$2.60 +0.11 (+4.42%)

Closing price 10/27/2026 04:00 PM Eastern

Extended Trading

$2.60 0.00 (-0.19%)

As of 10/27/2026 07:30 PM Eastern

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

Sarepta Therapeutics NASDAQ:SRPT

$18.89 +0.91 (+5.06%)

Closing price 10/27/2026 04:00 PM Eastern

Extended Trading

$18.88 -0.01 (-0.06%)

As of 10/27/2026 07:56 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CAPR, SRPT, and PEPG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CAPR, SRPT, and PEPG Earnings

Compare Dividends

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CAPR, SRPT, and PEPG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR, SRPT, and PEPG Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

PepGen NASDAQ:PEPG

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CAPR, SRPT, and PEPG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CAPR, SRPT, and PEPG Earnings

Compare Dividends

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CAPR, SRPT, and PEPG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR, SRPT, and PEPG Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

PepGen NASDAQ:PEPG

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools